|Dr. Joshua Lehrer-Graiwer FACC, M.D.||Pres, CEO & Director||561.28k||N/A||1974|
|Dr. Matthew Porteus M.D., Ph.D.||Academic Founder & Director||53.85k||N/A||1965|
|Dr. Maria Grazia Roncarolo M.D., Ph.D.||Academic Founder||53.65k||N/A||1954|
|Mr. Philip P. Gutry||Chief Bus. Officer, Head of Fin. & Investor Relations||170.45k||N/A||1973|
|Ms. Katherine Vega Stultz||Chief Operating Officer||335.83k||N/A||1973|
|Dr. Daniel Dever Ph.D.||Co-Founder & Head of Discovery Research||N/A||N/A||N/A|
|Mr. Jerry Cacia||Chief Technical Officer||N/A||N/A||1967|
|Dr. Jane Grogan Ph.D.||Chief Scientific Officer||N/A||N/A||1967|
|Ms. Julia Tran||Sr. VP of People||N/A||N/A||N/A|
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Graphite Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.